{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:02:51Z","timestamp":1779861771674,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jad.2025.119787","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:09:57Z","timestamp":1751454597000},"page":"119787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder"],"prefix":"10.1016","volume":"391","author":[{"given":"Prakash S.","family":"Masand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Nabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Kerolous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousam","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119787_bb0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1370\/afm.1260","article-title":"Severity of depression and magnitude of productivity loss","volume":"9","author":"Beck","year":"2011","journal-title":"Ann. Fam. Med."},{"key":"10.1016\/j.jad.2025.119787_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jad.2019.01.044","article-title":"Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder","volume":"249","author":"Citrome","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119787_bb0020","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2015.07.001","article-title":"Major depressive disorder: understanding the significance of residual symptoms and balancing efficacy with tolerability","volume":"128","author":"Culpepper","year":"2015","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jad.2025.119787_bb0025","first-page":"1335","article-title":"Annual costs among patients with major depressive disorder and the impact of key clinical events","volume":"28","author":"Cutler","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.jad.2025.119787_bb0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.genhosppsych.2007.06.002","article-title":"Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability","volume":"29","author":"Egede","year":"2007","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0035","series-title":"Esketamine [package insert]","year":"2019"},{"key":"10.1016\/j.jad.2025.119787_bb0040","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.euroneuro.2014.04.004","article-title":"Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial","volume":"24","author":"Fornaro","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.119787_bb0045","first-page":"1517","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2025.119787_bb0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-12-143","article-title":"Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment","volume":"12","author":"Garcia-Toro","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12888-017-1385-0","article-title":"Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis","volume":"17","author":"Gauthier","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0060","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2025.119787_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/JCP.0b013e31823f705d","article-title":"Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D","volume":"32","author":"Gaynes","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.119787_bb0070","series-title":"Practice Guidelines for the Treatment of Patients with Major Depressive Disorder","author":"Gelenberg","year":"2010"},{"key":"10.1016\/j.jad.2025.119787_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/da.22378","article-title":"The American Society of Clinical Psychopharmacology survey of psychopharmacologists\u2019 practice patterns for the treatment of mood disorders","volume":"32","author":"Goldberg","year":"2015","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2025.119787_bb0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States","volume":"39","author":"Greenberg","year":"2021","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jad.2025.119787_bb0085","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2015.04.020","article-title":"Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study","volume":"66-67","author":"Han","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.119787_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.genhosppsych.2011.10.001","article-title":"Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies","volume":"34","author":"Hansen","year":"2012","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12888-018-1657-3","article-title":"Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study","volume":"18","author":"Haro","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0100","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40801-022-00316-4","article-title":"Treatment patterns during major depressive episodes among patients with major depressive disorder: a retrospective database analysis","volume":"9","author":"Jain","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jad.2025.119787_bb0105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12888-022-04165-x","article-title":"Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis","volume":"22","author":"Jain","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0110","first-page":"896","article-title":"Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder","volume":"29","author":"Jain","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.jad.2025.119787_bb0115","first-page":"76","article-title":"Switching and stopping antidepressants","volume":"39","author":"Keks","year":"2016","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.jad.2025.119787_bb0120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2025.119787_bb0125","article-title":"Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)","volume":"363","author":"Kessler","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.119787_bb0130","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bdi.13035","article-title":"The 2020 Royal Australian and new Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary","volume":"22","author":"Malhi","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.119787_bb0135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2025.119787_bb0140","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m13988","article-title":"Remission and treatment augmentation of depression in the United States","volume":"82","author":"Mojtabai","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0145","series-title":"Depression in Adults: Treatment and Management","author":"National Institute for Health and Care Excellence (NICE)","year":"2022"},{"key":"10.1016\/j.jad.2025.119787_bb0150","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 6","key":"10.1016\/j.jad.2025.119787_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.8133su1c.03","article-title":"Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder","volume":"70","author":"Papakostas","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/10401230591002129","article-title":"A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic","volume":"17","author":"Papakostas","year":"2005","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0165","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4088\/JCP.v68n0602","article-title":"Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis","volume":"68","author":"Papakostas","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14656561003614781","article-title":"Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era","volume":"11","author":"Philip","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jad.2025.119787_bb0175","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.OT19037BR3","article-title":"Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies","volume":"81","author":"Rafeyan","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0180","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 6","key":"10.1016\/j.jad.2025.119787_bb0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.8133su1c.01","article-title":"Update on partial response in depression","volume":"70","author":"Thase","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119787_bb0195","first-page":"S2","article-title":"Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States","volume":"28","author":"Zhu","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725012297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725012297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:09:41Z","timestamp":1779858581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725012297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"alternative-id":["S0165032725012297"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119787","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119787"}}